Merck shares plunge as company pauses Gardasil vaccine shipments in China, hurting 2025 outlook
Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...
FiercePharma1d
Merck halts Gardasil shipments to China, withdraws $11B sales target as demand nosedives
The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...
Should You Pick MRK Stock At $90?
Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.
Merck's Gardasil Vaccine Slowdown In China Bites Again, Stock Falls On Weak 2025 Outlook
Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the ...
Merck Is Suffering From a Classic Pharma Problem
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...
BioSpace1d
Merck’s Gardasil Woes Grow as China Trade War Heats Up
Merck reported a 2% decline in Gardasil sales, after reaching a peak of $8.9 billion in 2023. Now with shipments to China paused, the HPV vaccine faces significant headwinds going into 2025.
STAT1d
Merck’s earnings miss focused attention on Gardasil. The real issue is Keytruda
Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...